Research programme: beta-amyloid fibrillogenesis inhibitors - Elan Pharmaceuticals/Neuralab
Alternative Names: beta-amyloid fibrillogenesis inhibitors research programme - Elan Pharmaceuticals/Neuralab; Research programme: amyloid-beta fibrillogenesis inhibitors - Elan Pharmaceuticals/NeuralabLatest Information Update: 24 Jun 2003
At a glance
- Originator Elan Corporation; Neuralab
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 23 Apr 2001 Preclinical development for Alzheimer's disease in USA (Unknown route)